OMRON (6645) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
13 Jun, 2025Executive summary
Consolidated revenue and profits declined year-over-year in H1 FY2024/FY2025, but results exceeded internal plans.
Operating income increased in Q2 due to improved gross profit margin and fixed cost reductions, though H1 operating income was down 6.9% year-over-year to ¥19.2 bn.
Net loss attributable to shareholders was ¥3.3 bn, mainly due to ¥21.0 bn in one-time restructuring expenses.
Gross profit margin improved to 45.4% from 42.9% year-over-year, despite lower sales.
Interim dividend set at ¥52; full-year dividend guidance maintained at ¥104.
Financial highlights
H1 FY2024 net sales: ¥374.6 bn, down 6.5% year-over-year; gross profit: ¥170.0 bn (45.4% margin).
Operating income: ¥19.2 bn, down 6.9% year-over-year; net income attributable to shareholders: -¥3.3 bn (impacted by one-time reform expenses).
Full-year FY2024 forecast: net sales revised down to ¥805.0 bn, operating income revised up to ¥52.0 bn, net income revised up to ¥11.0 bn.
EPS forecast raised to ¥56; ROE and ROIC both around 1%.
Total assets stood at ¥1,349.2 bn, with a shareholders' equity ratio of 56.6%.
Outlook and guidance
Full-year sales forecast revised down due to continued sluggish demand in key markets, but operating income and net income forecasts revised up on improved GPM and cost controls.
Forecast includes approximately ¥22.0 bn in one-time restructuring costs for headcount and capacity optimization.
Dividend forecast maintained at ¥104 per share for the full year.
H2 business environment expected to recover slowly, with continued weakness in China and Europe.
Latest events from OMRON
- Revenue and net sales up YoY, net income nearly doubled, and full-year guidance raised.6645
Q3 20265 Feb 2026 - Sales up 5%, profit guidance raised as automation and data outperform, healthcare lags.6645
Q2 202619 Nov 2025 - Net income rebounded to ¥6.8bn as automation and device growth offset healthcare weakness.6645
Q1 20266 Aug 2025 - Sales and profit fell sharply on restructuring costs, but full-year outlook is maintained.6645
Q1 202513 Jun 2025 - Profits surged on margin gains; FY2025/26 outlook cautious amid tariff risks.6645
Q4 20259 Jun 2025 - Profit outlook raised as margin gains offset sales drop and restructuring costs.6645
Q3 20259 Jun 2025